Spotlighting Lessons Learned in Tumour Model Selection to Advance ADC Development

• Highlighting the pros and cons of CDX and PDX models
• Discussing strategies to empower tumour model selection to better study underserved patient populations
• Leveraging findings from the models to tackle ADC payload toxicity and dosing strategies for mice versus humans

Speakers:

Christophe Côme

Director - Pharmacology

Adcendo ApS